Merck snaps up preclinical Lexington biotech for up to $773M

Tilos Therapeutics, a quiet preclinical biotech developing treatments for cancer and autoimmune diseases, has become the latest startup to be acquired by pharmaceutical giant Merck& Co. Merck (NYSE: MRK) announced Monday that it has agreed to pay upwards of $773 million in upfront and milestone payments for the purchase. A company spokesperson declined to disclose how much Merck paid upfront. Privately held Tilos was founded in 2016 by Boehringer Ingelheim Venture Fund and Partn ers Healthcare’s…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news